Corrigendum to “pH-Sensitive Tacrolimus loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease” [Eur. J. Pharm. Biopharm. 204 (2024) 114461] (European Journal of Pharmaceutics and Biopharmaceutics (2024) 204, (S093964112400287X), (10.1016/j.ejpb.2024.114461))

The authors regret “In our recently published article titled “[pH-Sensitive Tacrolimus loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease”” in [European Journal of Pharmaceutics and Biopharmaceutics. 2024 Sep: EJPB_114461], it has come to our attention that incorrect affiliation were inadvertently included due to an oversight. We sincerely apologize for this error. The affected address is C. The correct address, which accurately represent the affiliation of an author of the study, are provided below. These address should replace in the previously published ones. We confirm that the corrected address do not affect the overall idea and reported results of the manuscript. Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, KSA. We appreciate the understanding of the readers and the editorial team, and we regret any confusion this may have caused. The authors would like to apologise for any inconvenience caused.